$TOVX
Theriva Biologics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000114420418058414 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.474M $1.710M
YoY Change -13.8% -18.57%
% of Gross Profit
Research & Development $16.00K $4.137M
YoY Change -99.61% -41.41%
% of Gross Profit
Depreciation & Amortization $67.00K $50.00K
YoY Change 34.0% 0.0%
% of Gross Profit
Operating Expenses $4.320M $5.842M
YoY Change -26.05% -36.19%
Operating Profit -$4.320M -$5.842M
YoY Change -26.05% -36.19%
Interest Expense $5.000K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $631.0K -$5.088M
YoY Change -112.4% -862.82%
Pretax Income -$4.320M -$5.842M
YoY Change -26.05% -36.19%
Income Tax
% Of Pretax Income
Net Earnings -$3.689M -$10.93M
YoY Change -66.25% 28.75%
Net Earnings / Revenue
Basic Earnings Per Share -$0.93 -$4.90
Diluted Earnings Per Share -$0.93 -$4.90
COMMON SHARES
Basic Shares Outstanding 4.028M 3.665M
Diluted Shares Outstanding 4.028M 3.665M

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.549M $21.05M
YoY Change -54.64% 362.64%
Cash & Equivalents $9.549M $21.05M
Short-Term Investments
Other Short-Term Assets $473.0K $1.260M
YoY Change -62.46% 328.57%
Inventory
Prepaid Expenses $230.0K $406.0K
Receivables
Other Receivables $86.00K $612.0K
Total Short-Term Assets $10.11M $22.31M
YoY Change -54.69% 192.02%
LONG-TERM ASSETS
Property, Plant & Equipment $665.0K $940.0K
YoY Change -29.26% 62.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $20.00K
YoY Change 15.0% -33.33%
Total Long-Term Assets $688.0K $970.0K
YoY Change -29.07% 59.02%
TOTAL ASSETS
Total Short-Term Assets $10.11M $22.31M
Total Long-Term Assets $688.0K $970.0K
Total Assets $10.80M $23.28M
YoY Change -53.63% 182.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $879.0K $1.100M
YoY Change -20.09% -74.06%
Accrued Expenses $1.485M $3.680M
YoY Change -59.65% 30.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.914M $17.53M
YoY Change -77.67% 25.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $329.0K $430.0K
YoY Change -23.49% 104.76%
Total Long-Term Liabilities $329.0K $430.0K
YoY Change -23.49% 104.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.914M $17.53M
Total Long-Term Liabilities $329.0K $430.0K
Total Liabilities $4.243M $16.08M
YoY Change -73.61% 26.42%
SHAREHOLDERS EQUITY
Retained Earnings -$204.5M
YoY Change
Common Stock $200.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.733M $7.200M
YoY Change
Total Liabilities & Shareholders Equity $10.80M $23.28M
YoY Change -53.63% 182.18%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$3.689M -$10.93M
YoY Change -66.25% 28.75%
Depreciation, Depletion And Amortization $67.00K $50.00K
YoY Change 34.0% 0.0%
Cash From Operating Activities -$3.599M -$4.520M
YoY Change -20.38% -24.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$200.0K
YoY Change -100.0% 33.33%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$200.0K
YoY Change -100.0% 33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -400.0K 12.40M
YoY Change -103.23% 1837.5%
NET CHANGE
Cash From Operating Activities -3.599M -4.520M
Cash From Investing Activities 0.000 -200.0K
Cash From Financing Activities -400.0K 12.40M
Net Change In Cash -3.999M 7.680M
YoY Change -152.07% -239.64%
FREE CASH FLOW
Cash From Operating Activities -$3.599M -$4.520M
Capital Expenditures $0.00 -$200.0K
Free Cash Flow -$3.599M -$4.320M
YoY Change -16.69% -26.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9549000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17116000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
559000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
827000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
10108000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
17943000 USD
CY2018Q3 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000 USD
CY2017Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000 USD
CY2018Q3 us-gaap Assets
Assets
10796000 USD
CY2017Q4 us-gaap Assets
Assets
18838000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
879000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2020000 USD
CY2018Q3 syn Warrant Liabilities
WarrantLiabilities
19000 USD
CY2018Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1434000 USD
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2074000 USD
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
97000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
90000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3914000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9793000 USD
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
329000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
402000 USD
CY2018Q3 us-gaap Liabilities
Liabilities
4243000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
10195000 USD
CY2018Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12234000 USD
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12053000 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
200807000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192670000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204545000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194170000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-3733000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-1496000 USD
CY2018Q3 us-gaap Minority Interest
MinorityInterest
-1948000 USD
CY2017Q4 us-gaap Minority Interest
MinorityInterest
-1914000 USD
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5681000 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3410000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10796000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18838000 USD
CY2017 syn Deferred Tax Assetsfederal And Statutory Income Tax Rate
DeferredTaxAssetsfederalAndStatutoryIncomeTaxRate
0.21 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
21600000 USD
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
98000 USD
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
98000 USD
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
230000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
94000 USD
CY2018Q3 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
184000 USD
CY2017Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
290000 USD
CY2018Q3 us-gaap Prepaid Insurance
PrepaidInsurance
59000 USD
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
351000 USD
CY2018Q3 syn Clinical Consulting Services Refund Receivable
ClinicalConsultingServicesRefundReceivable
0 USD
CY2017Q4 syn Clinical Consulting Services Refund Receivable
ClinicalConsultingServicesRefundReceivable
46000 USD
CY2018Q3 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
0 USD
CY2017Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
46000 USD
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1301000 USD
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
636000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
429000 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
872000 USD
CY2018Q3 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1167000 USD
CY2017Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
658000 USD
CY2018Q3 syn Accrued Vendor Payments
AccruedVendorPayments
243000 USD
CY2017Q4 syn Accrued Vendor Payments
AccruedVendorPayments
193000 USD
CY2018Q3 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
64000 USD
CY2017Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
661000 USD
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14000 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1485000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1526000 USD
CY2018Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1007000 USD
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1283000 USD
CY2018Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
289000 USD
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
201000 USD
CY2018Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
138000 USD
CY2017Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
590000 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1434000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2074000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5346674 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3675668 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5344346 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3673340 shares
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1474000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1705000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4525000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5440000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2846000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4137000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9788000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15028000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
4320000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
5842000 USD
us-gaap Operating Expenses
OperatingExpenses
14313000 USD
us-gaap Operating Expenses
OperatingExpenses
20468000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4320000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5842000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14313000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20468000 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
20000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
631000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5088000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4084000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2164000 USD
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-3689000 USD
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-10930000 USD
us-gaap Profit Loss
ProfitLoss
-10229000 USD
us-gaap Profit Loss
ProfitLoss
-18304000 USD
CY2018Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 USD
CY2017Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-35000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-280000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-3680000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-10922000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10194000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18024000 USD
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
61000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
181000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6901000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3741000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17823000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10375000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24925000 USD
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.90
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.00
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4028304 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3665134 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3802812 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3512868 shares
CY2017Q4 syn Warrant Liabilities
WarrantLiabilities
4083000 USD
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
915138 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
714 shares
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
915852 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
52.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.20
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
52.48
CY2018Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4214000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10375000 USD
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4028304 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3802812 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4028304 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3802812 shares
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.73
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.73
CY2017Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17823000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24925000 USD
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3665134 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3512868 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3665134 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3512868 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.00
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
166000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6422000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6358000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6422000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18476000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-7567000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
1995000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.00
CY2018Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.885 pure
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6901000 USD
CY2018Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-626000 USD
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5092000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4064000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2157000 USD
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1070000 USD
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.02 pure
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6900000 USD
CY2017Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
73000 USD
CY2018Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
59000 USD
CY2018Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
62000 USD
CY2018Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
60000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1708000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2906000 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
9000 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
207000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
172000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-268000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1251000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1141000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-895000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-41000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-557000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19055000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21050000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
11952000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
209000 USD
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132969743 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3799136 shares
CY2018Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty-five (35) shares of common stock (the “Reverse Stock Split”)
CY2018Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
86000 USD
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-640000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1293000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-66000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
19000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13989000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16272000 USD
CY2018Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
181000 USD
CY2017Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 USD
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
SYN
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13483976 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
false

Files In Submission

Name View Source Status
0001144204-18-058414-index-headers.html Edgar Link pending
0001144204-18-058414-index.html Edgar Link pending
0001144204-18-058414.txt Edgar Link pending
0001144204-18-058414-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20180930.xml Edgar Link completed
syn-20180930.xsd Edgar Link pending
syn-20180930_cal.xml Edgar Link unprocessable
syn-20180930_def.xml Edgar Link unprocessable
syn-20180930_lab.xml Edgar Link unprocessable
syn-20180930_pre.xml Edgar Link unprocessable
tv505582_10q.htm Edgar Link pending
tv505582_ex31-1.htm Edgar Link pending
tv505582_ex32-1.htm Edgar Link pending
tv505582_img1.jpg Edgar Link pending